Treatment of Moderate to Severe Lateral Canthal Lines

Summary

The objective of the study is to evaluate the efficacy and safety of a single dose of QM1114-DP compared to placebo for the treatment of moderate to severe LCL.

Timeline

Start

2020-02-10

Primary completion

2020-09-25

Completion

2021-02-10

Outcome

Met primary endpoint

release “Both studies met their primary endpoints with significantly higher response than placebo after one month for both frown lines and crow’s feet” galderma.com ↗

Drugs

Indications